Drug Search Results
More Filters [+]

Adebrelimab

Alternative Names: Adebrelimab, shr-1316, shr1316, shr 1316, hti-1088, hti1088
Latest Update: 2024-07-08
Latest Update Note: Clinical Trial Update

Product Description

SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.

Mechanisms of Action: PD-L1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Hengrui Medicine Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Adebrelimab

Countries in Clinic: Australia, China, Unknown Location

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma

Phase 2: Adenocarcinoma|Biliary Tract Cancer|Bronchogenic Carcinoma|Cervical Cancer|Cholangiocarcinoma|Colorectal Cancer|Esophageal Cancer|Gastrointestinal Cancer|Hepatocellular Carcinoma|Male Breast Cancer|Oncology Solid Tumor Unspecified|Uterine Cancer

Phase 1: Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SHR-1316-307

P3

Not yet recruiting

Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer

2028-10-01

LungMate-015

P3

Not yet recruiting

Small Cell Lung Cancer

2027-08-01

SHR-8068-201-BTC

P2

Recruiting

Biliary Tract Cancer

2026-12-30

23-OBU-FJ-HCC-II-012

P2

Recruiting

Hepatocellular Carcinoma

2026-11-15

Recent News Events